Free rapid antigen tests makes public health sense and economic sense.
Articles on SARS-CoV-2
Displaying 141 - 160 of 605 articles
SARS-CoV-2 cannot improve indefinitely.
DNA sequencing has allowed researchers to catch new COVID-19 variants hours after receiving the first positive test sample.
Nearly all suicide-loss survivors experience guilt, wondering what they could have done to prevent it. But despite decades of research, experts struggle to identify risk factors and predict suicide.
Rapid testing for COVID-19 is an extra safety measure that can help prevent spread of infection, and help you have a more normal holiday, especially if you are visiting vulnerable people.
Early data show that Omicron is dominating new COVID-19 cases in Gauteng province.
At this stage, we cannot say anything about the severity of cases with Omicron - either in primary or reinfections.
Knowing when and how often to use rapid tests is key to getting an accurate picture of your COVID-19 status.
Careful lab work will complement public health data as researchers worldwide focus on omicron, asking questions about contagiousness, severity of disease and whether vaccines hold up against it.
It’s worth having a conversation with family and friends to set some rules to minimise the risk of COVID transmission.
Efforts to improve vaccine uptake must be tailored to the needs and concerns of the individuals and families who make up society.
How we should manage uncertainty is not a scientific issue but an ethical issue.
After a nose swab tests positive for a virus or bacteria, scientists can use the sample’s genetic sequence to figure out where and when the pathogen emerged and how fast it’s changing.
It’s too early to say whether the newly identified omicron variant is going to overtake delta. But particular mutations in the new strain have researchers deeply concerned.
US researchers have designed a special chewing gum to target SARS-CoV-2. But at this stage, it’s only been tested in a lab – not on real people.
Not much data, but lessons have been learned from the slow response to delta.
There’s not enough evidence yet to support the AstraZeneca CEO’s statement. But it is theoretically plausible.
The world needs to learn to live with the virus. And governments must follow the science and don’t distort it for political expediency.
There’s a new COVID lineage called B.1.1.529. It has a genetic profile very different from other circulating variants
The quest to find treatment for COVID-19, and the uncertainty surrounding the clinical outcome, necessitates the use of antibiotics in the treatment package.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor, Epidemiology, Deakin University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Associate Professor and Research Leader in Virology and Infectious Disease, Griffith University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Instructor of Human Immunology, Emory University
-
Professor Emerita, Nursing, School of Nursing and Midwifery, Griffith University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Scientific Officer in Biomedical Sciences, University of Leeds
-
Postdoctoral Fellow in Virology and Immunology, University of Colorado Boulder
-
Professor of Molecular, Cellular and Developmental Biology, University of Colorado Boulder
-
Lecturer in Virology, Queen's University Belfast